Accelerated vs conventional Alog dose-escalation in Chinese children with house dust mite allergic rhinoconjunctivitis

Phase 4, randomised, open-label trial of alogliptin in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Foshan Maternity & Child Healthcare Hospital. Primary endpoint: Total adverse events and serious adverse events, including treatment-related adverse events and serious adverse events. Planned start Sep 2021; status: not yet recruiting.